{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:49:28Z","timestamp":1793170168486,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Chronische Entz\u00fcndungserkrankungen (engl. \u201eimmune-mediated inflammatory diseases\u201c [IMID]) sind mit einer erheblichen Krankheitslast verbunden. Diese ist umso ausgepr\u00e4gter, sofern diese gleichzeitig bei Patienten auftreten oder z.\u202fB. weitere Komorbidit\u00e4ten bestehen. Die Versorgung der IMID ist komplex und involviert diverse medizinische Fachdisziplinen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel der Arbeit<\/jats:title>\n                <jats:p>Die Beschreibung der Krankheitslast und der aktuellen Arzneimittelversorgung der Patienten mit IMID.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Die retrospektive Querschnittanalyse erfolgte unter Nutzung von Abrechnungsdaten der gesetzlichen Krankenversicherung der InGef-Datenbank. Unter 3.988.695 Versicherten wurden im Jahr 2018 anhand dokumentierter Diagnosen (ICD-10-GM) pr\u00e4valente Patienten mit Psoriasis (Pso), Psoriasisarthritis (PsA), Spondyloarthritiden (SpA), rheumatoider Arthritis (RA), Morbus Crohn (MC), Colitis ulcerosa (CU) oder Kollagenosen identifiziert. Das gemeinsame Auftreten verschiedener IMID sowie weiterer Begleiterkrankungen wurde im Vergleich zur Referenzpopulation untersucht. Die medikament\u00f6se Versorgung wurde basierend auf vordefinierten Therapieformen beschrieben.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Im Jahr 2018 wurden 188.440\u00a0Patienten mit IMID (4,7\u202f%) identifiziert. Im Vergleich zur Referenzpopulation war die Pr\u00e4valenz von depressiven Episoden und kardiovaskul\u00e4ren Risikoerkrankungen bei Patienten mit IMID h\u00f6her. Bei MC, CU, RA, und PsA wurden DMARDs (engl. \u201edisease-modifying antirheumatic drugs\u201c) und klassische systemische Therapien am h\u00e4ufigsten eingesetzt. Bei Pso, SpA und Kollagenosen waren NSAR (nichtsteroidale Antirheumatika) die h\u00e4ufigsten Therapieformen oft in Kombination mit anderen Wirkstoffen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Ein betr\u00e4chtlicher Anteil der Patienten mit IMIDs (16,9\u201327,5\u202f%) leidet an unterschiedlichen Erkrankungen des IMID-Formenkreises. Sie sind h\u00e4ufig von Begleiterkrankungen betroffen und bed\u00fcrfen einer interdisziplin\u00e4ren medizinischen Versorgung.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00393-022-01306-1","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T20:03:16Z","timestamp":1672862596000},"page":"200-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chronische Entz\u00fcndungserkrankungen in Deutschland","Immune-mediated inflammatory diseases in Germany"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9684-9700","authenticated-orcid":false,"given":"Jan","family":"Leipe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Schmelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Sch\u00e4kel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Linke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina C.","family":"Manz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Bartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"Roecken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimba F.","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"1306_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca\u00a0R, Heslinga\u00a0S, Rollefstad\u00a0S et\u00a0al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis 76:17\u201328","journal-title":"Ann Rheum Dis"},{"key":"1306_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00393-022-01192-7","volume":"81","author":"K Albrecht","year":"2022","unstructured":"Albrecht\u00a0K, Callhoff\u00a0J, Strangfeld\u00a0A (2022) Is the prevalence of rheumatoid arthritis truly on the rise? Z\u00a0Rheumatol 81:323\u2013327","journal-title":"Z Rheumatol"},{"key":"1306_CR3","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1007\/s12325-019-00964-z","volume":"36","author":"D Aletaha","year":"2019","unstructured":"Aletaha\u00a0D, Epstein\u00a0AJ, Skup\u00a0M et al (2019) Risk of developing additional immune-mediated manifestations: a\u00a0retrospective matched cohort study. Adv Ther 36:1672\u20131683","journal-title":"Adv Ther"},{"key":"1306_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn\u00a0F, Walker\u00a0J (2016) Characteristics and external validity of the German health risk institute (HRI) database. Pharmacoepidemiol Drug Saf 25:106\u2013109","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1306_CR5","first-page":"33","volume":"116","author":"Anonymous","year":"2019","unstructured":"Anonymous (2019) Tofacitinib in der Rheumatologie: Indikation Psoriasis-Arthritis. Dtsch Arztebl Int 116:33","journal-title":"Dtsch Arztebl Int"},{"key":"1306_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00393-018-0568-5","volume":"78","author":"C Baerwald","year":"2019","unstructured":"Baerwald\u00a0C, Manger\u00a0B, Hueber\u00a0A (2019) Depression as comorbidity of rheumatoid arthritis. Z\u00a0Rheumatol 78:243\u2013248","journal-title":"Z Rheumatol"},{"key":"1306_CR7","first-page":"197","volume":"114","author":"J Braun","year":"2017","unstructured":"Braun\u00a0J, Kruger\u00a0K, Manger\u00a0B et\u00a0al (2017) Cardiovascular comorbidity in inflammatory rheumatological conditions. Dtsch Arztebl Int 114:197\u2013203","journal-title":"Dtsch Arztebl Int"},{"key":"1306_CR8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/acr.20408","volume":"63","author":"A Bremander","year":"2011","unstructured":"Bremander\u00a0A, Petersson\u00a0IF, Bergman\u00a0S et al (2011) Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 63:550\u2013556","journal-title":"Arthritis Care Res"},{"key":"1306_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates\u00a0LC, Soriano\u00a0ER, Corp\u00a0N et\u00a0al (2022) Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18:465\u2013479","journal-title":"Nat Rev Rheumatol"},{"key":"1306_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/acr.22536","volume":"67","author":"F Ernste","year":"2015","unstructured":"Ernste\u00a0F, S\u00e1nchez-Men\u00e9ndez\u00a0M, Wilton\u00a0K et al (2015) Cardiovascular risk profile at the onset of psoriatic arthritis: a\u00a0population-based cohort study. Arthritis Care Res 67:1015\u20131021","journal-title":"Arthritis Care Res"},{"key":"1306_CR11","doi-asserted-by":"publisher","first-page":"adv00553","DOI":"10.2340\/00015555-3906","volume":"101","author":"S Felbo Kamp","year":"2021","unstructured":"Felbo Kamp\u00a0S, Terslev\u00a0L, S\u00f8rensen\u00a0IJ et al (2021) Musculoskeletal pain in patients with psoriasis and its influence on health-related quality of life: results from a\u00a0Danish population-based survey. Acta Derm Venereol 101:adv553","journal-title":"Acta Derm Venereol"},{"key":"1306_CR12","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1111\/j.1572-0241.2000.02262.x","volume":"95","author":"JB Felder","year":"2000","unstructured":"Felder\u00a0JB, Korelitz\u00a0BI, Rajapakse\u00a0R et al (2000) Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a\u00a0case-control study. Am J Gastroenterol 95:1949\u20131954","journal-title":"Am J Gastroenterol"},{"key":"1306_CR13","volume-title":"S2e-Leitline: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten","author":"C Fiehn","year":"2018","unstructured":"Fiehn\u00a0C, Holle\u00a0J, Iking-Konert\u00a0C et al (2018) S2e-Leitline: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u202fV."},{"key":"1306_CR14","volume-title":"Entz\u00fcndlich-rheumatische Erkrankungen","author":"Gesundheitsberichterstattung Des Bundes","year":"2010","unstructured":"Gesundheitsberichterstattung Des Bundes (2010) Entz\u00fcndlich-rheumatische Erkrankungen"},{"key":"1306_CR15","first-page":"ii14","volume":"64","author":"D Gladman","year":"2005","unstructured":"Gladman\u00a0D, Antoni\u00a0C, Mease\u00a0P et\u00a0al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64:ii14\u2013ii17","journal-title":"Ann Rheum Dis"},{"key":"1306_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec\u00a0L, Baraliakos\u00a0X, Kerschbaumer\u00a0A et\u00a0al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79:700\u2013712","journal-title":"Ann Rheum Dis"},{"key":"1306_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/ibd.20873","volume":"15","author":"LA Graff","year":"2009","unstructured":"Graff\u00a0LA, Walker\u00a0JR, Bernstein\u00a0CN (2009) Depression and anxiety in inflammatory bowel disease: a\u00a0review of comorbidity and management. Inflamm Bowel Dis 15:1105\u20131118","journal-title":"Inflamm Bowel Dis"},{"key":"1306_CR18","first-page":"445","volume":"20","author":"I Hansen","year":"2022","unstructured":"Hansen\u00a0I, Augustin\u00a0M, Schafer\u00a0I et al (2022) Epidemiology of skin diseases in Germany: systematic review of the current state of research\u2014part 2: non-infectious skin diseases. J\u00a0Dtsch Dermatol Ges 20:445\u2013455","journal-title":"J Dtsch Dermatol Ges"},{"key":"1306_CR19","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1136\/ard.2004.032318","volume":"64","author":"P Helliwell","year":"2005","unstructured":"Helliwell\u00a0P, Taylor\u00a0W (2005) Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 64:ii3\u2013ii8","journal-title":"Ann Rheum Dis"},{"key":"1306_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s41971-019-00063-4","volume":"17","author":"C H\u00f6genauer","year":"2019","unstructured":"H\u00f6genauer\u00a0C, H\u00e4usler\u00a0D, Pieringer\u00a0H et\u00a0al (2019) Interdisziplin\u00e4res Management immunmediierter Erkrankungen \u2013 eine \u00f6sterreichische Perspektive. J\u00a0Gastroenterol Hepatol Erkr 17:108\u2013124","journal-title":"J Gastroenterol Hepatol Erkr"},{"key":"1306_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/01.MIB.0000160809.38611.f7","volume":"11","author":"K-H Janke","year":"2005","unstructured":"Janke\u00a0K\u2011H, Klump\u00a0B, Gregor\u00a0M et al (2005) Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis 11:272\u2013286","journal-title":"Inflamm Bowel Dis"},{"key":"1306_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00393-019-0670-3","volume":"78","author":"U Kiltz","year":"2019","unstructured":"Kiltz\u00a0U, Braun\u00a0J, Becker\u00a0A et al (2019) Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Fr\u00fchformen, Update 2019. Z\u00a0Rheumatol 78:3\u201364","journal-title":"Z Rheumatol"},{"key":"1306_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s10198-012-0432-5","volume":"14","author":"PA Laires","year":"2012","unstructured":"Laires\u00a0PA, Exposto\u00a0F, Mesquita\u00a0R et\u00a0al (2012) Patients\u2019 access to biologics in rheumatoid arthritis: a\u00a0comparison between Portugal and other European countries. Eur J Health Econ 14:875\u2013885","journal-title":"Eur J Health Econ"},{"key":"1306_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000481335","volume":"5","author":"SJ Lockwood","year":"2017","unstructured":"Lockwood\u00a0SJ, Prens\u00a0LM, Kimball\u00a0AB (2017) Unerw\u00fcnschte Wirkungen von Biologika bei Psoriasis. Kompass Dermatol 5:195\u2013199","journal-title":"Kompass Dermatol"},{"key":"1306_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.genhosppsych.2018.06.001","volume":"53","author":"RA Marrie","year":"2018","unstructured":"Marrie\u00a0RA, Walld\u00a0R, Bolton\u00a0JM et al (2018) Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. Gen Hosp Psychiatry 53:65\u201372","journal-title":"Gen Hosp Psychiatry"},{"key":"1306_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-014-0418-z","volume":"16","author":"JJ Meesters","year":"2014","unstructured":"Meesters\u00a0JJ, Bremander\u00a0A, Bergman\u00a0S et al (2014) The risk for depression in patients with ankylosing spondylitis: a\u00a0population-based cohort study. Arthritis Res Ther 16:1\u20135","journal-title":"Arthritis Res Ther"},{"key":"1306_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0713-3","volume":"17","author":"CS Moura","year":"2015","unstructured":"Moura\u00a0CS, Abrahamowicz\u00a0M, Beauchamp\u00a0M\u2011E et al (2015) Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a\u00a0large population-based study. Arthritis Res Ther 17:1\u20139","journal-title":"Arthritis Res Ther"},{"key":"1306_CR28","first-page":"S1","volume-title":"S3-Leitlinie zur Therapie der Psoriasis vulgaris Update 2017","author":"A Nast","year":"2017","unstructured":"Nast\u00a0A, Amelunxen\u00a0L, Augustin\u00a0M et al (2017) S3-Leitlinie zur Therapie der Psoriasis vulgaris Update 2017. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u202fV., S S1\u2013S156"},{"key":"1306_CR29","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng\u00a0SC, Shi\u00a0HY, Hamidi\u00a0N et al (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a\u00a0systematic review of population-based studies. Lancet 390:2769\u20132778","journal-title":"Lancet"},{"key":"1306_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/abd1806-4841.20153038","volume":"90","author":"MDFSPD Oliveira","year":"2015","unstructured":"Oliveira\u00a0MDFSPD, Rocha\u00a0BDO, Duarte\u00a0GV (2015) Psoriasis: classical and emerging comorbidities. An Bras Dermatol 90:9\u201320","journal-title":"An Bras Dermatol"},{"key":"1306_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3899\/jrheum.110899","volume":"88","author":"AS Russell","year":"2011","unstructured":"Russell\u00a0AS, Gulliver\u00a0WP, Irvine\u00a0EJ et al (2011) Quality of life in patients with immune-mediated inflammatory diseases. J\u00a0Rheumatol Suppl 88:7\u201319","journal-title":"J Rheumatol Suppl"},{"issue":"1","key":"1306_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00393-020-00775-6","volume":"79","author":"M Schneider","year":"2020","unstructured":"Schneider\u00a0M, Baseler\u00a0G, Funken\u00a0O (2020) Management der fr\u00fchen rheumatoiden Arthritis: Interdisziplin\u00e4re Leitlinie. Z\u00a0Rheumatol 79(1):1\u201338","journal-title":"Z Rheumatol"},{"key":"1306_CR33","doi-asserted-by":"publisher","first-page":"100519","DOI":"10.1016\/j.lanepe.2022.100519","volume":"23","author":"IC Scott","year":"2022","unstructured":"Scott\u00a0IC, Whittle\u00a0R, Bailey\u00a0J et\u00a0al (2022) Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data. Lancet Reg Health Eur 23:100519","journal-title":"Lancet Reg Health Eur"},{"key":"1306_CR34","volume-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","author":"JS Smolen","year":"2020","unstructured":"Smolen\u00a0JS, Landew\u00e9\u00a0RB, Bijlsma\u00a0JW et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update"},{"key":"1306_CR35","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/annrheumdis-2018-214746","volume":"78","author":"LJ van Mens","year":"2019","unstructured":"van Mens\u00a0LJ, de Jong\u00a0HM, Fluri\u00a0I et al (2019) Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a\u00a0double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis 78:610\u2013616","journal-title":"Ann Rheum Dis"},{"key":"1306_CR36","first-page":"323","volume":"116","author":"M Walter","year":"2019","unstructured":"Walter\u00a0M (2019) Chronisch entz\u00fcndliche Darmerkrankungen: Januskinase-Hemmung gegen Colitis ulcerosa. Dtsch Arztebl Int 116:323","journal-title":"Dtsch Arztebl Int"},{"key":"1306_CR37","first-page":"72","volume":"113","author":"J Wehkamp","year":"2016","unstructured":"Wehkamp\u00a0J, G\u00f6tz\u00a0M, Herrlinger\u00a0K et\u00a0al (2016) Chronisch entz\u00fcndliche Darmerkrankungen. Dtsch Arztebl Int 113:72\u201382","journal-title":"Dtsch Arztebl Int"},{"key":"1306_CR38","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s00393-016-0094-2","volume":"75","author":"A Zink","year":"2016","unstructured":"Zink\u00a0A, Albrecht\u00a0K (2016) How frequent are musculoskeletal diseases in Germany? Z\u00a0Rheumatol 75:346\u2013353","journal-title":"Z Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01306-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01306-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01306-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:05:08Z","timestamp":1711548308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01306-1"}},"subtitle":["Eine Querschnittanalyse \u00fcber Begleiterkrankungen und Arzneimitteleinsatz","A cross-sectional analysis of comorbidities and pharmacotherapy"],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01306-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"21 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die Autor:innen J.\u00a0Leipe, R.\u00a0Schmelz, G.\u00a0Riemekasten, D.\u00a0Tha\u00e7i, J.\u00a0Henes, K.\u00a0Sch\u00e4kel, A.\u00a0Pinter, M.\u00a0Sticherling, J.\u00a0Wegner, S.\u00a0Fusco, M.\u00a0Linke, V.\u00a0Weber, K.C.\u00a0Manz, H.\u00a0Bartz, M.\u00a0Roecken, S.\u00a0Schmidt und B.F.\u00a0Hoyer verzeichnen Vortragshonorare von und eine Beratert\u00e4tigkeit f\u00fcr die Janssen-Cilag GmbH oder sind Mitarbeiter der Janssen-Cilag GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}